Scroll

galantamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1272	357-70-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: galantamine galantamin galantamina lycoremin lycoremine galanthamine (-)-Galantamine (-)-Galanthamine galantamine hydrobromide galanthamine hydrobromide	A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. Molecular weight: 287.36 Formula: C17H21NO3 CLOGP: 1.02 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 41.93 ALOGS: -2.23 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

galantamine
galantamin
galantamina
lycoremin
lycoremine
galanthamine
(-)-Galantamine
(-)-Galanthamine
galantamine hydrobromide
galanthamine hydrobromide

A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.

Molecular weight: 287.36
Formula: C17H21NO3
CLOGP: 1.02
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 41.93
ALOGS: -2.23
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
16	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.45 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.83 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 28, 2001	FDA	JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Orthostatic hypotension	1217.80	40.90	359	7446	32840	56251422
Sedation complication	1211.23	40.90	288	7517	11384	56272878
Creatinine renal clearance decreased	1178.01	40.90	294	7511	14265	56269997
Sedation	1139.88	40.90	345	7460	34509	56249753
Cognitive disorder	1099.26	40.90	364	7441	48769	56235493
Blood calcium decreased	1026.08	40.90	292	7513	23477	56260785
Balance disorder	927.32	40.90	360	7445	76160	56208102
Depressed level of consciousness	833.20	40.90	307	7498	56126	56228136
Mobility decreased	619.55	40.90	292	7513	98699	56185563
Constipation	599.80	40.90	362	7443	201581	56082681
Fall	598.22	40.90	448	7357	357062	55927200
Hypotension	547.42	40.90	370	7435	250138	56034124
Toxicity to various agents	433.98	40.90	308	7497	224256	56060006
Pain	144.73	40.90	296	7509	662888	55621374
Drug ineffective	95.48	40.90	9	7796	918980	55365282
Fatigue	63.15	40.90	16	7789	788536	55495726
Product dispensing error	53.53	40.90	26	7779	9238	56275024
Pleurothotonus	51.28	40.90	15	7790	1306	56282956
Marasmus	45.21	40.90	11	7794	471	56283791
Multiple drug therapy	43.95	40.90	16	7789	2776	56281486
Hallucination	41.28	40.90	42	7763	49107	56235155

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fall	60.72	24.58	82	2998	186007	31508257
Dysphagia	36.71	24.58	36	3044	57640	31636624
Post-traumatic stress disorder	35.31	24.58	11	3069	1698	31692566
Aggression	35.04	24.58	29	3051	37262	31657002
Dementia	34.72	24.58	19	3061	12341	31681923
Compartment syndrome	34.29	24.58	12	3068	2659	31691605
Fracture	33.67	24.58	15	3065	6265	31687999
Hallucination	33.39	24.58	31	3049	46379	31647885
Agitation	31.14	24.58	32	3048	54137	31640127
Increased bronchial secretion	26.68	24.58	9	3071	1785	31692479

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	1269.57	30.49	309	9784	13101	70905250
Creatinine renal clearance decreased	1193.18	30.49	309	9784	16891	70901460
Orthostatic hypotension	1097.22	30.49	371	9722	51372	70866979
Sedation	1081.81	30.49	358	9735	46373	70871978
Cognitive disorder	1075.76	30.49	381	9712	60575	70857776
Blood calcium decreased	1026.31	30.49	307	9786	28539	70889812
Balance disorder	900.01	30.49	372	9721	89756	70828595
Depressed level of consciousness	792.51	30.49	337	9756	87094	70831257
Mobility decreased	651.97	30.49	309	9784	102690	70815661
Fall	632.55	30.49	512	9581	443584	70474767
Constipation	548.68	30.49	376	9717	252062	70666289
Hypotension	446.94	30.49	404	9689	403977	70514374
Toxicity to various agents	332.40	30.49	335	9758	381837	70536514
Pain	177.35	30.49	318	9775	628498	70289853
Drug ineffective	74.48	30.49	21	10072	939731	69978620
Dementia	49.77	30.49	34	10059	22331	70896020
Marasmus	46.80	30.49	13	10080	915	70917436
Pleurothotonus	42.30	30.49	15	10078	2351	70916000
Multiple drug therapy	41.46	30.49	16	10077	3176	70915175
Fatigue	39.11	30.49	36	10057	824283	70094068
Arthralgia	36.62	30.49	13	10080	503377	70414974
Headache	34.42	30.49	20	10073	580385	70337966
Hallucination	34.29	30.49	48	10045	76212	70842139
Bradycardia	32.19	30.49	61	10032	124554	70793797
Poriomania	31.23	30.49	7	10086	203	70918148

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06DA04	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
FDA MoA	N0000000177	Cholinesterase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D002800	Cholinesterase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018697	Nootropic Agents
MeSH PA	D010277	Parasympathomimetics
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175723	Cholinesterase Inhibitor
CHEBI has role	CHEBI:37733	EC 3.1.1.8 inhibitor
CHEBI has role	CHEBI:38323	cholinergic drugs
CHEBI has role	CHEBI:38462	acetylcholinesterase inhibitors
CHEBI has role	CHEBI:74530	curare poisoning antidote
CHEBI has role	CHEBI:76924	plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alzheimer's disease	indication	26929004	DOID:10652
Diffuse Lewy body disease	off-label use	80098002
Moderate to Severe Alzheimer's Type Dementia	off-label use
Peptic ulcer	contraindication	13200003	DOID:750
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Gastrointestinal ulcer	contraindication	40845000
Bradycardia	contraindication	48867003
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Asthma	contraindication	195967001	DOID:2841
Atrioventricular block	contraindication	233917008	DOID:0050820
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN	INHIBITOR	Ki	7.21	CHEMBL	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	6.72	CHEMBL
Acetylcholinesterase	Enzyme		ACES_TORCA		IC50	6.44	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		IC50	5.60	CHEMBL
Butyrylcholinesterase; Protein Bche	Enzyme		Q9JKC1_RAT		IC50	5.23	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	6.27	CHEMBL
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	6.37	CHEMBL
Acetylcholinesterase	Enzyme		ACES_BOVIN		IC50	5.06	CHEMBL
Butyrylcholinesterase	Enzyme		Q9N1N9_HORSE		Ki	5.10	CHEMBL
Cholinesterase	Enzyme		CHLE_HORSE		Ki	5.03	CHEMBL

External reference:

ID	Source
4021250	VUID
N0000148691	NUI
D02173	KEGG_DRUG
1953-04-4	SECONDARY_CAS_RN
4021250	VANDF
4021251	VANDF
C0016967	UMLSCUI
CHEBI:42944	CHEBI
GNT	PDB_CHEM_ID
CHEMBL659	ChEMBL_ID
DB00674	DRUGBANK_ID
CHEMBL1555	ChEMBL_ID
D005702	MESH_DESCRIPTOR_UI
9651	PUBCHEM_CID
6693	IUPHAR_LIGAND_ID
1392	INN_ID
0D3Q044KCA	UNII
4637	RXNORM
147848	MMSL
15913	MMSL
d04750	MMSL
007026	NDDF
007027	NDDF
129482002	SNOMEDCT_US
323377002	SNOMEDCT_US
395727007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Galantamine Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0137	SOLUTION	4 mg	ORAL	ANDA	24 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3496	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3496	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3497	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3497	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3498	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3498	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7104	TABLET, FILM COATED	4 mg	ORAL	ANDA	26 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0881	TABLET, FILM COATED	4 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0881	TABLET, FILM COATED	4 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0882	TABLET, FILM COATED	8 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0882	TABLET, FILM COATED	8 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0883	TABLET, FILM COATED	12 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0883	TABLET, FILM COATED	12 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0891	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0891	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0892	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0892	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0893	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	NDA	28 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0893	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	NDA	28 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-184	TABLET, FILM COATED	8 mg	ORAL	NDA	20 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-591	TABLET, FILM COATED	12 mg	ORAL	NDA	20 sections
Galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	43353-984	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	20 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-835	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-835	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-836	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-836	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-837	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-837	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-387	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	NDA	27 sections